(1)
Collaborative mice study with UC San Diego to study brain development from embryo to old age
Berwyn, Pennsylvania (Newsfile Corp. - April 29, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer s disease (AD), Parkinson s disease (PD) and other neurodegenerative diseases, today announced a new research collaboration with Professor William Mobley and Dr. Xuqiao Chen at the University of California San Diego designed to study the ability of the Company s lead compound, ANVS401, to normalize brain development in Down Syndrome (DS) mice. While we know quite a bit about how the brain degenerates in the later stages of life, extraordinarily little is known about how neurodegeneration may start very early in life. We, therefore, plan to look at the brain in embryonic development in DS mice, said Maria Maccecchini, Ph.D., Founder and Chief Executive Officer.